IDT Australia Limited reported sales results for the third quarter ended March 2023. For the quarter, revenue jumped 26% to $2.14 million over the previous quarter (and +168% over two quarters) due primarily to contracts won in IDT's Specialty Orals division. The demand outlook for Specialty Orals manufacturing is growing due to several factors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1 AUD | 0.00% | 0.00% | -9.09% |
May. 06 | IDT Australia Secures Victorian Government Funding for Cancer Medication Production Facility | MT |
Apr. 16 | IDT Australia Signs Master Service Agreement with Sanofi | MT |
1st Jan change | Capi. | |
---|---|---|
-9.09% | 23.44M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.30% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- IDT Stock
- News IDT Australia Limited
- IDT Australia Limited Reports Sales Results for the Third Quarter Ended March 2023